TAZORAC Drug Patent Profile

When do Tazorac patents expire, and what generic alternatives are available?

Tazorac is a drug marketed by Allergan and is included in two NDAs.

The generic ingredient in TAZORAC is tazarotene. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tazarotene profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tazorac

A generic version of TAZORAC was approved as tazarotene by TARO on April 3^rd, 2017.

Summary for TAZORAC

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	129
Clinical Trials:	21
Patent Applications:	5,802
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TAZORAC
What excipients (inactive ingredients) are in TAZORAC?	TAZORAC excipients list
DailyMed Link:	TAZORAC at DailyMed

See drug prices for TAZORAC

See drug sales revenues for TAZORAC

Recent Clinical Trials for TAZORAC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dana-Farber Cancer Institute	Phase 2
Bayer	Phase 2
Dr. Reddy's Laboratories Limited	Phase 2

See all TAZORAC clinical trials

Pharmacology for TAZORAC

Drug Class

Retinoid

Anatomical Therapeutic Chemical (ATC) Classes for TAZORAC

D05AX	Other antipsoriatics for topical use
D05A	ANTIPSORIATICS FOR TOPICAL USE
D05	ANTIPSORIATICS
D	Dermatologicals

US Patents and Regulatory Information for TAZORAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	TAZORAC	tazarotene	CREAM;TOPICAL	021184-001	Sep 29, 2000		RX	Yes	Yes
Allergan	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997	AB	RX	Yes	Yes
Allergan	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000	AB	RX	Yes	Yes
Allergan	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997	AB	RX	Yes	Yes

Expired US Patents for TAZORAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997
Allergan	TAZORAC	tazarotene	CREAM;TOPICAL	021184-001	Sep 29, 2000
Allergan	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997
Allergan	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997
Allergan	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997
Allergan	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997
Allergan	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000

International Patents for TAZORAC

See the table below for patents covering TAZORAC around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2227559
Hong Kong	5794	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID LIKE ACTIVITY
China	1026789
China	88101424
Japan	H07503733
Germany	69533484
Australia	3659193

Supplementary Protection Certificates for TAZORAC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0031058	98C0008	Belgium		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
0284288	12/1998	Austria		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
0284288	SPC/GB98/002	United Kingdom		PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730